- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office
- NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
- NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
- NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
- NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
- NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
- NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
- NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
- NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
More ▼
Key statistics
On Wednesday, NewAmsterdam Pharma Company NV (KH6:FRA) closed at 17.90, -21.49% below its 52-week high of 22.80, set on Mar 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.90 |
---|---|
High | 17.90 |
Low | 17.90 |
Bid | 18.30 |
Offer | 18.90 |
Previous close | 18.20 |
Average volume | 0.00 |
---|---|
Shares outstanding | 89.98m |
Free float | 84.84m |
P/E (TTM) | -- |
Market cap | 1.83bn USD |
EPS (TTM) | -2.70 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 14:29 BST.
More ▼